“…Although this syndrome presently afflicts more than 47 million people in the United States (1, 48), defining specific causes underlying this perfusion/demand mismatch has been challenging, as previous studies in human subjects have determined that alterations to vascular reactivity (12, 13, 15, 31), a progressive structural narrowing of individual vessels (46, 47, 51), and a developing reduction in the density of microvessels within skeletal muscle (38, 58) can all occur during the metabolic syndrome in afflicted individuals. Each of these conditions has the potential to elevate vascular resistance (27, 45) and compromise the ability of skeletal muscle to resist fatigue through impairments in the processes of mass transport and exchange (42,43,49,52).We have recently investigated skeletal muscle vascular and microvascular consequences of evolution of the metabolic syndrome in the obese Zucker rat (OZR), a model of this condition that results from chronic hyperphagia experienced by the animal as a result of a deficient leptin receptor gene (7,8).In adult OZR, we have determined that microvessel density within gastrocnemius muscle is markedly reduced and that this reduction contributes, with a structural narrowing of individual skeletal muscle microvessels (18, 54) and an augmentation in vascular ␣-adrenergic reactivity (17, 55), to elevate the vascular resistance to perfusion and the rate at which skeletal muscle fatigues with elevated metabolic demand (19).Our previous study examining impairments in skeletal muscle perfusion in OZR has suggested that although an enhanced vascular ␣-adrenergic reactivity contributes significantly to reduced blood flow under resting conditions, this process does not play a role in blunting muscle perfusion with more substantial increases in metabolic demand (17). We have also previously determined that an acute amelioration of vascular oxidant stress, substantially elevated in OZR, does not improve functional hyperemia in skeletal muscle, despite considerable improvements in the agonist-induced dilator reactivity of arterioles (19,21,22).…”